Nebraska Medicine has released new guidance addressing one of the most common concerns women face when considering hormone replacement therapy: whether it increases cancer risk. The clarification comes as more women seek relief from debilitating menopausal symptoms, yet remain hesitant due to lingering fears about HRT’s safety profile.
According to the Nebraska Medicine experts, the relationship between HRT and cancer risk is more nuanced than many patients realize. While certain types of hormone therapy may slightly increase the risk of breast cancer with long-term use, the absolute risk remains relatively small for most women. The guidance emphasizes that estrogen-only therapy, typically prescribed for women who have had hysterectomies, actually carries a lower breast cancer risk than combined estrogen-progestin therapy.
The institution’s position reflects evolving medical understanding since the Women’s Health Initiative study of 2002, which initially caused widespread alarm about HRT safety. Modern research indicates that timing matters significantly—women who begin HRT closer to menopause onset and use it for shorter durations face minimal increased risk. Nebraska Medicine notes that for many women, particularly those experiencing severe hot flashes, night sweats, or bone density loss, the benefits of symptom relief and osteoporosis prevention may outweigh potential risks.
The guidance also addresses other cancer concerns beyond breast cancer. Evidence suggests HRT may slightly reduce colorectal cancer risk, while its effect on ovarian and endometrial cancer depends on the specific hormone formulation and whether progesterone is included to protect the uterine lining.
For patients weighing their options, Nebraska Medicine recommends individualized risk assessment with healthcare providers. Factors including personal and family cancer history, age at menopause, symptom severity, and overall health should guide decision-making. The institution emphasizes that for appropriately selected women, HRT remains a safe and effective treatment option, particularly when initiated during the critical window shortly after menopause begins and used at the lowest effective dose for the shortest necessary duration.
